Minsheng Securities released a research report on April 23 stating that it gave Nootai Biotech (688076.SH) a recommended rating. The main reasons for the rating include: 1) independent business selection supports rapid growth in performance, and the matrix BD team accelerates the expansion of global orders; 2) the third-generation peptide production workshop was completed and put into operation to prepare for the development of more top international customers. (Mainichi Keizai Shimbun)
民生证券4月23日发布研报称，给予诺泰生物（688076.SH）推荐评级。评级理由主要包括：1）自主选择业务支持业绩高速增长，矩阵式BD团队加速拓展全球订单；2）第三代多肽生产车间建成投产，为开拓更多国际顶级客户做准备。（每日经济新闻）
Minsheng Securities released a research report on April 23 stating that it gave Nootai Biotech (688076.SH) a recommended rating. The main reasons for the rating include: 1) independent business selection supports rapid growth in performance, and the matri
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.